Trial Profile
A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Servier 1 (Primary) ; Idelalisib
- Indications Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Novartis
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 20 Jun 2018 Planned End Date changed from 29 Jun 2018 to 2 Jul 2018.
- 19 Apr 2018 Planned End Date changed from 22 Jun 2019 to 29 Jun 2018.